5 December 2017
EMA/805958/2017

EMEA/H/C/000745

Public statement

Optimark

Expiry of the marketing authorisation in the European Union

The marketing authorisation for Optimark (gadoversetamide) expired on 25 July 2017 following the decision of the marketing authorisation holder, Guerbet, not to apply for a renewal of the marketing authorisation.

Optimark was granted marketing authorisation in the European Union (EU) on 23 July 2007 for use with magnetic resonance imaging (MRI) of the central nervous system and the liver.

The marketing authorisation was valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2012.

The European Public Assessment Report (EPAR) for Optimark will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact